|
| Case no | Preoperative DA dose and duration | PRL after initial DA (μg/L) | Tumor volume after initial DA (cm3)† | Indication for surgery | Surgery type | Tumor pathology features |
|
| 1 | N/A | N/A | N/A | Misdiagnosis, vision loss | Craniotomy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
| 2 | Cab 2.5 mg/wk for 36 mos | 4,156
(19% increase) | N/A–not measured | DA resistance and intolerance, vision loss, tumor apoplexy | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining, Ki-67 1-2%
Tumor fibrosis |
| 3 | Cab 1 mg/wk for 3 mos | 262 (76% decrease) | 39.4
(44% increase) | DA resistance, vision loss | Transsphenoidal using microscopy, incomplete resection | Benign, diffuse PRL stain, ACTH co-staining
(No co-secretion) |
| 4 | Cab 1 mg/wk for 3 weeks | 172
(93% decrease) | 20.0
(12% decrease) | CSF leak, DA intolerance, vision loss | Transsphenoidal using microscopy, incomplete resection | Benign, diffuse PRL stain, GH and TSH co-staining (no co-secretion) |
| 5 | Cab 2 mg/wk for 2 weeks | 364
(47% decrease) | 37.2
(20% increase) | DA resistance, vision loss | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
| 6 | Cab 3.5 mg/wk for 18 mos | 5,754
(>56% decrease) | 27.4
(11% decrease) | DA resistance and intolerance | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining
Tumor fibrosis |
| 7 | N/A | N/A | N/A | Misdiagnosis, vision loss | Craniotomy, incomplete resection | Benign, diffuse PRL stain, no co-staining |
| 8 | Cab 3.5 mg/wk for 10 mos | 1,917
(83% decrease) | 23.9
(49% decrease) | CSF leak, DA resistance and intolerance | Transsphenoidal endoscopy, incomplete resection | Benign, diffuse PRL stain, no co-staining, Ki-67 20%
Tumor fibrosis |
|
